Greetings. Welcome to the CryoLife’s Third Quarter 2013 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Steve Anderson, President and CEO for CryoLife. Thank you, Mr. Anderson. You may begin.

Good morning, everyone. This is Steve Anderson, CryoLife’s President and CEO, and I would like to welcome you to CryoLife’s third quarter conference call. With me today is Ashley Lee, the company’s Executive Vice President, COO and CFO. This morning we announced record revenues and record earnings for the third quarter. Revenues were $36.3 million up 8% from $33.4 million in 2012. And earnings per share were $0.11 up from $0.06 in the third quarter of 2012. The agenda for today’s call is as follows; Ashley will discuss the third quarter results in detail and by product line. He will discuss the significant financial gain that we realized in the fourth quarter on our investments in Medafor common stock as a result of their acquisition by C.R. Bard. He will comment on our ongoing corporate development activities. He will also comment on our continuing stock buyback initiatives. Last, he will comment on our corporate expansion into the Pacific Rim countries. I will discuss the PerClot IDE submission and the approximate timetable for its approval and the beginning of the human clinical trials. I will also comment on the recent cardiovascular fellows training program that we sponsored in September. After my comments Ashley will return to give you an update on our financial guidance for the rest of the year. At the conclusion of Ashley’s guidance comments, we will open the call for questions. At this time, Ashley will comment on this morning’s earnings release.

Thanks Steve. To comply with the Safe Harbor requirements of the Private Securities Litigation Reform Act of 1995, I would like make the following statement. Comments made in this call that look forward in time involve risk and uncertainties and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements include statements made as to the company’s or management’s intentions, hopes, beliefs, expectations or predictions of the future, including the guidance for 2013 that I will provide in a moment. Additional information concerning risk and uncertainties that may impact these forward-looking statements is contained from time to time in the company’s SEC filings, including the Risk Factor section of our previously filed Form 10-K for the year ended December 31, 2012, and our subsequently filed Form 10-Qs for the first three quarter’s of 2013, and in the press release that went out this morning. This morning we reported our results for the third quarter and first nine months of 2013. We continued to make progress on executing our strategy of leveraging additional high margin products to drive revenue growth and are pleased with our results from that perspective in the third quarter. We achieved record quarterly revenues at $36.3 million driven by year-over-year revenue growth from BioGlue, Tissue Processing, PerClot and Revascularization Technologies or TMR. We were particularly pleased with the strong growth in our higher margin product segment, which help drive third quarter EPS of $0.11. In addition, last week, we received an initial payment of $15.4 million in connection with the sale of our investment in Medafor which bolsters our already strong balance sheet and will further support our growth initiatives. The following factors influenced our revenue performance. We saw strong revenue growth in all geographies. Our domestic revenues were…

On September 27, we resubmitted our IDE for PerClot to the FDA. As you will recollect, we had received a conditional approval from FDA on June 14 of this year. This revised and updated application includes indications for cardiovascular, urology, general and orthopedics surgical indications. Final FDA approval is required before we can begin to enroll patients and conduct the trial. The trial as submitted will be comprised of 320 patients. There will be 160 patients in the experimental group and 160 patients in the controlled group with one month follow up. We anticipate that enrollment will take about seven months. We are expecting to receive PMA approval for PerClot in the second half of 2015 depending on how quickly we complete enrollment. In prior conference calls, we’ve made comments about certain product features of PerClot that we feel are superior to Medafor’s Arista. Among the features that we feel are significantly better is the fact that PerClot absorbs about 4x to 5x the amount of water that Arista absorbs. In addition, PerClot’s water absorption rate is significantly faster as compared to Arista and makes a more adhesive gel to resist dislodgement from the wound. We continue to believe that the U.S. market for powdered hemostat in 2014 will be about $1.1 [ph] billion. On September 18, through the 20th, we hosted a surgical workshop attended by cardiovascular surgery residents and fellows from across the United States. Many of the top medical schools were represented at this meeting. The meeting concentrated on aortic valve repair, aortic valve replacements, aortic reconstruction and the Ross procedure. This training program was focused on cardiovascular surgery residents and fellows who of course may well be future implanters of our process tissue and users of our other products. The course directors are William F. Northrup, III, M.D, Vice President of Physician Relationships and Education here at CryoLife and George L. Hicks Jr., MD, Chief of Cardiac Surgery and Professor of Surgery at the University of Rochester Medical Center in Rochester, New York. They were assisted by 11 other faculty members who are professors and surgery from various medical schools. We had received positive feedback on the workshop from the faculty and attendees and remain committed to providing advanced medical training for our customers. That concludes my comments and now Ashley will return to give you some financial guidance for the rest of the year.

Our updated 2013 financial guidance was included in our press release that went out this morning. In summary, we increased our range of earnings per share guidance to $0.58 to $0.60 per share primarily to reflect our strong third quarter performance and the gain on the sale of our investment in Medafor. Note that our EPS guidance can be materially affected by a variety of factors including the magnitude of our R&D and clinical trial expenses; expenses related to potential future business development litigation and share repurchases which cannot currently be estimated. We believe that we are continuing to successfully execute on our strategy of positioning the company for accelerated revenue and earnings growth by expanding our addressable market opportunities through internal R&D, expanding and leveraging our sales and marketing and executing on business development opportunities. Looking forward, we believe that we have several opportunities to expand the company’s market opportunity with higher growth, higher margin products. These include one, continue to drive revenue growth in the HeRO Graft through the launch in our broader U.S. direct sales force and the market launch in Europe; two, initiate enrollment in our PerClot IDE clinical trial and pursue additional marketing approvals in new international markets; three continued to expand our European sales and marketing coverage for PerClot to include other surgical specialties in addition to cardiac and vascular surgery; four, seek expanded indications for BioGlue in Japan and regulatory approval for PerClot in Japan and BioGlue in China; five, build on our commitment to the Asia Pacific region by retaining distribution partners for our products in new markets such as China and Southeast Asia; six drive our TMR business through our clinical registry and increased laser console evaluations; and finally seven, continue to evaluate business development opportunities. If we execute on these initiatives, we will be in a good position to drive top line growth on our higher margin medical products and further leverage our operating infrastructure to improve profitability. That concludes my comments and I will turn it back over to Steve.

At this time, we would like to open up the call for questions.

Thank you. We will now be conducting a question-and-answer session. (Operator Instructions) Thank you. Our first question comes from the line of Jeffrey Cohen of Ladenburg. Please proceed with your question.

Oh, hi. Thanks for taking my questions in a nice quarter.

Thanks Jeff.

So when will you put on any type of guidance on fiscal 2014?

We typically issued our initial guidance in our February year-end conference call. So it looks like February of next year when we will have our initial 2014 guidance.

Okay. And your quarter should be submitted tomorrow or today?

The 10-Q?

Yes.

Later today or tomorrow at the latest.

Okay. Can you talk about some of the M&A opportunities in the general environment and prices out there and products out there that exists that you can look at?

We are currently looking at two already approved products that would be tuck-in acquisitions into the cardiac [indiscernible] of the vascular area of our company. We are in early discussions. I can’t say anything more about them at this time. There is plenty of opportunities out there Jeff just simply because of the lack of venture money and investment capital and small one product companies in the medical device segment continue to struggle and need working capital and we are talking to a number of them at this time.

Okay. That’s helpful. Steve, you commented before so you resubmitted your IDE for PerClot on September 27, can you review for me the specific label on the indications you said cardiovascular urology, general and orthopedics.

Yes. We expected to hear from them by today meaning this month. But, of course, because of the shutdown in Washington undoubtedly has been delayed. But I was very confident that we will hear before the end of October. So that’s probably have been pushed out by a couple of weeks.

Okay. So that would be -- your submission was expected as filed?

No. We are just continuing dialog between our regulatory department and FDA. So they are working their way through the issues and the questions that they had is just I think the general governmental shutdown has negatively affected that. Jeffrey Cohen – Ladenburg: Okay. So you will put out an 8-K when your [ph] submittal was accepted?

You sure that we will.

Okay. And –

Maybe have gone through it. Jeffrey Cohen – Ladenburg: And number of centers for a trial to get started?

It will be up to 15 centers. Jeffrey Cohen – Ladenburg: Up to 15 domestic or European, all domestic?

Yes. Jeffrey Cohen – Ladenburg: Up to 15 centers. Okay, got you. Just a couple of more [indiscernible] the – so for Q4, is the gain from Medafor for the sale approximately $12.5 million, is that a good number to use?

Yes. That’s about right. Jeffrey Cohen – Ladenburg: That’s about right, okay.

Yes. Jeffrey Cohen – Ladenburg: Okay. So that’s $0.54 obviously before tax, so you are stripping out about $0.29 for that after tax, so your guidance goes up from by about a nickel to $0.29 to $0.31 it looks like if you strike that off?

That’s correct. Jeffrey Cohen – Ladenburg: That’s a good estimate. Okay. And it look like just on a couple of product numbers, so any specific commentary as far as cardiac tissue for the quarter which appeared very strong?

Cardiac tissue was very strong in the quarter. Third quarter is typically one of our stronger quarters because of all of the pediatric surgeries that are done in the summer months. In addition to that we made some changes internally that resulted in getting some tissues cleared through our system more quickly and I think that’s all reflected in our third quarter numbers. Jeffrey Cohen – Ladenburg: Okay. And how did that relate to the much higher margins for preservation services for the quarter? Was that just better throughput or more inventory coming out of – more product coming out of inventory at lower margins?

I think the larger part of it was just due to product mix. Our long segment [indiscernible] tissues in particular did extremely well. We also had a small price increase in the middle of year two. So there is a combination of a couple of factors. Jeffrey Cohen – Ladenburg: Okay. And lastly, any commentaries specific to any seasonality, I mean typically Q3, why it looks like it may have been a little life for you only as it relates to a few of the products but not necessarily overall. So how might that relate to Q4 or is that some commentary that you comment on after Q4?

Well, I will just say based on what we are seeing right now, we expect to be at least in the middle to upper part of our range of revenue guidance. So we expect to have a good fourth quarter. Jeffrey Cohen – Ladenburg: Okay. And so year-over-year it’s turning out to be higher single digits than previously expected?

If we end up at the upper end of our range of guidance, answer will be yes. Jeffrey Cohen – Ladenburg: Or beyond it?

Yes. Jeffrey Cohen – Ladenburg: Okay. Okay, perfect. Thanks guys.

Okay.

Thank you. (Operator Instructions) Our next question comes from the line of Joe Munda of Sidoti. Please proceed with your question.

Good morning, guys. Thank you for taking the questions.

Hi, Joe.

Let me start off, Ashley on the guidance you talked about HeRO Graft revenue and in the prepared remarks you talked about entering new market with a broader launch in 2014 for Europe. But, I’m looking at the guidance here and HeRO revenues you guys have revised it down, well or narrowed the range from $5.5 million to $6.5 million to $5.5 million to $5.7 million. I’m just a little curious as to why, is it maybe taking longer for you to launch that product into Europe and any color would be great.

Not necessarily in Europe, the European plans are going according to plan, we are going to have a controlled launch this year and we weren’t expecting a big contribution in 2013. I think what we are seeing is, developing the referral channels is one of the things that we continue to work at, the gatekeeper to this particular patient as [indiscernible] as opposed to the vascular surgeon. And it has taken us a little bit longer than we initially thought in order to develop that referral network but we continue to get very good feedback out in the field. And with this upcoming Central Venous Pathology summit that we have coming up, we think that’s going to help jump start the program to. So even though we are a little bit lower than where we wanted to be. We are still very optimistic about the program.

Got it. That’s helpful. Also here you guys talked about preservation services growth, it was very nice in the quarter here, but I picked up that [ph] advance healer unit volume had decreased but overall growth in the segment was up roughly I’m looking at 8% for the quarter. I’m just trying to get a sense of how much volume decrease did you see and what were the fee increases?

We saw but low -- very low single digit decrease in vascular volume. We did see a favorable mix shift into our longer segment [indiscernible] ASPs. And then we also had a mid-single digit increase in prices in the middle of the year too. So combination of all of those factors led to the result that we saw for tissues in the quarter.

And that increase in the fees, is that carry into 2014, are these or we’re looking at possibly another fee increase in 2014?

Possibly another in 2014.

Okay. On the P&L front, as far as general administrative cost and prepared remarks you spoke about Hemosphere cost roughly $800,000 in the quarter basically due to the business development and integration cost, when can we see some of that dissipate or we expecting to see that carry into 2014?

I think you’ll start to see it dissipate almost right now. Over the first I would say couple of quarters of this year into the third quarter, we migrated the manufacturing from Minneapolis down to Atlanta. And in the first half of this year, we were really like validating the facility and readying it for manufacturing and those are really kind of the integration cost that that you saw. We are now manufacturing that product at our facilities here in Atlanta and the integration cost that you saw previously are now going to be part of our product cost.

Okay. So, looking at it, just [indiscernible] on this quarter, I mean you guys had $16.5 million in G&A, is that a number expected to -- I mean obviously is proportion of the revenue but is that number expected to raise going forward with the trials going on. I know that it’s primarily R&D but how should we look at it, is G&A going to decrease proportionately to total sales going forward?

We’ll certainly going to continue to have to invest to support the business going forward. So you should expect to see some increase in G&A expenses going forward. Our goal over time is to have as you would expect, our G&A expenses that we increased in G&A be less than what we were experiencing on the top line increase. So that’s our plan to get realized more operating leverage as we move forward. With that being said, you probably can expect to see some increase in G&A and again in February of next year, we’ll give out our 2014 guidance with a little bit more clarity.

Okay. And I just got two more real quick. On the R&D line, it appears as well in your guidance, you guys revised it down. I’m assuming that you’re hoping to get this trial started a lot sooner. So going forward in 2014, I know you don't give guidance there. But is it safe to assume that the guidance you gave for $11 million to $12 million in R&D expense would carry over into 2014, is that something that we’re looking at due to the impact of this IDE?

Again, we haven’t given our guidance on the 2014 R&D number. I will say this though Joe, we expect the cost to complete the clinical trial from this point going forward to be somewhere in the range of $5 million to $6 million. And the timing of when that expense will fall is going to be largely depending upon the enrollment in the study. So we certainly expect our R&D to increase in 2014 as compared to 2013 whether you would expect to see a full $5 million to $6 million increase over this year’s run rate. I’m not prepared to guide to that at this point. We’ll have more clarity in the conference call in February.

I understand that. But I think Steve had mentioned that he is expecting TMA approval in the second half of 2015, correct?

Right.

So that’s $5 million to $6 million we are looking at probably in the first and second quarter, right because I mean --?

There will be some follow-up too but yes, I mean a large portion of it will probably occur sometime during 2014. But there again there were other projects that we were working on in 2013 that won’t be recurring in 2014 either.

Okay.

So yes, even though we might see the full $5 million to $6 million next year. There are other things that you had been working this year that we are not going to be working on in 2014.

And then finally, the $40 million cash balance that you guys stated at the end of the month here, you talked about some acquisitions, I’m just curious with C.R. Bard acquiring Medafor and you guys from a competitive standpoint for the U.S. looking at second half 2015, it seems like they have a little bit of a jump start on you guys and C.R Bard obviously is a large company. How do you anticipate really gaining physician awareness in the product when it is approved and can be sold in U.S. and also the $40 million, are there any acquisitions in the surgical sealant side or the products that you are looking at? Thank you.

I will take the first part of that question. I don’t know if you have ever seen the demonstration of Arista and PerClot side by side but you need to do that. It is shocking any difference in the reaction of the products one to another. And our clinical trial is head to head comparison of those two products as requested by the FDA and we were delighted to do that because it’s a – you can’t quite believe your eyes when you see them difference between the activity. I think we will also have an opportunity to bundle our haemostatic agent with the BioGlue’s going to move forward. And we do have close to 60 people in the field and the cardiovascular area both cardiac and vascular and I think that we’ll be able to compete well there. We have been competing with Baxter and others for 10 years, 12 years maybe more. So I’m looking forward to the approval of that product because it’s so obviously superior.

Okay. Thank you.

Thank you. At this time there are no further questions. I will now turn the floor back to Mr. Anderson for closing comments.

Thank you for joining us today and we look forward to talking with you again in February for our year-end conference call.